Analytical method development, identification, and characterization of stress degradation products of idelalisib by ultrahigh‐performance liquid chromatography with photodiode array and ultrahigh‐performance liquid chromatography with electrospray ionization quadrupole time‐of‐flight mass spectrometry studies

Author:

Mahesh Marella1,Bali Alka1ORCID,Gupta Tanvi1

Affiliation:

1. University Institute of Pharmaceutical Sciences, UGC Center of Advanced Study Panjab University Chandigarh India

Abstract

RationaleAs per International Council for Harmonization (ICH) drug stability test guideline Q1A(R2), inherent stability characteristics of a drug should be studied. This work was designed to investigate inherent degradation characteristics of the drug idelalisib under ICH prescribed stress conditions, identify its degradation products, and postulate their corresponding degradation pathways.MethodsIdelalisib was subjected to the ICH prescribed conditions of hydrolytic (neutral, acidic, and alkaline), photolytic, oxidative, and thermal stress according to ICH guideline Q1A(R2). An ultrahigh‐performance liquid chromatography with photodiode array (UHPLC‐PDA) method was developed to adequately resolve the drug from its degradation products, validated as per the ICH guidelines, and subsequently extended to UHPLC with electrospray ionization quadrupole time‐of‐flight mass spectrometry (ESI‐QTOFMS) studies to identify the degradation products.ResultsSignificant degradation was noted under conditions of acidic/alkaline hydrolysis, acid photolysis, and oxidative stress. The UHPLC/ESI‐QTOFMS studies revealed the generation of four degradation products (I–IV), which were satisfactorily resolved from the drug by UHPLC on a Kinetex® C18 (100 × 4.6 mm; 2.6 μm) column by the developed isocratic elution method. Detection wavelength was selected as 270 nm. All the degradation products (I–IV) could be identified and characterized from their mass spectral data. The degradation pathways for the generation of various products from the drug were postulated.ConclusionsA UHPLC‐PDA method was developed and validated for idelalisib. Four degradation products of idelalisib were revealed through UHPLC/ESI‐QTOFMS studies, and corresponding degradation pathways were postulated for the same.

Publisher

Wiley

Reference19 articles.

1. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes

2. Zydelig (idelalisib): First‐in‐class PI3 kinase inhibitor approved for the treatment of 3 hematologic malignancies;Raedler LA;Am Health Drug Benefits,2015

3. Accessed April 30 2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20654 5lBl.pdf

4. Zydelig® (idelalisib).Highlights of prescribing information.2014. Accessed November 15 2020.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf Accessed April 30 2022.http://www.ema.europa.eu/ema/index.jsp?curl¼human/medicines/003843/human_med_001803.jsp

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3